Yau T, et al. Checkmate 459: a randomized, multi-center phase 3 study of nivolumab (nivo) vs sorafenib (sor) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (AHCC). Abstract LBA38_PR. ESMO Congress 2019, 28 sept. Barcelona, Spanje.
Op zoek naar de perfecte dosis carboplatine bij longkanker
feb 2024 | Borstkanker, Gynaecologische oncologie, Longoncologie